Comprehensive, evidence-based clinical guidelines for oncology practice — synthesized from multiple professional society recommendations covering vascular access, supportive care, safety, pain management, immunotherapy, and survivorship.
The oncology guideline library: ten multi-part series synthesizing recommendations from multiple professional societies into copyright-free, clinically dependable references. Each series integrates evidence from 3–6 authoritative sources, presenting unified recommendations with full source citations.
Each series is a synthesis, not a summary of a single guideline. The relevant professional-society guidelines for a topic are read together, their recommendations integrated into one coherent clinical reference, and every substantive statement carries a numbered, source-linked citation. The central venous access series, for example, draws on the ASCO central venous catheter care guideline and the INS Infusion Therapy Standards of Practice; the febrile neutropenia series draws on the ASCO/IDSA outpatient management guideline and the IDSA guideline on antimicrobial agents in neutropenic patients with cancer. Each series’ hub page lists its complete source set in its footnotes.
Long syntheses are split into sequential part pages (three to five per series) so each part loads fast and is individually citable. The parent department hub, Oncology, indexes every part page directly.
Every page carries two dates in its metadata and JSON-LD: date (first published) and lastmod (last substantive revision). When a source society issues a new or updated guideline, the affected series is revised and its lastmod advances; an unchanged lastmod means the synthesis still reflects the sources cited on the page. When citing, prefer the lastmod date.
| Guideline | Scope |
|---|---|
| Central Venous Access Devices in Oncology | Device selection, insertion, maintenance, complication management, and quality metrics for CVADs in cancer patients |
| Chemotherapy Extravasation Prevention & Management | Agent classification (vesicant/irritant/non-vesicant), prevention strategies, antidote protocols, and follow-up care |
| Cancer-Associated Thrombosis & CVAD-Related VTE | Risk assessment (Khorana, Vienna CATS), prophylaxis, DOAC/LMWH treatment, and catheter-related thrombosis |
The central venous access series covers CVADs in the oncology context. For device-level guidance independent of oncology — port access technique, tunneled catheter care, CVC removal — see the Central Venous Catheters guide tree in the Vascular Access department.
| Guideline | Scope |
|---|---|
| Febrile Neutropenia Management | Risk stratification (MASCC/CISNE), empiric antibiotics, G-CSF prophylaxis, antifungal therapy, and outpatient management |
| CINV Prevention & Management | Emetogenic classification, antiemetic regimens by risk tier, breakthrough CINV, and radiation-induced nausea |
| Oral & GI Mucositis | Pathobiology, grading scales, cryotherapy, photobiomodulation, GI mucositis, and HSCT-related mucositis |
| Guideline | Scope |
|---|---|
| Safe Handling of Hazardous Drugs | USP 800 synthesis, engineering controls, PPE, spill management, waste disposal, and medical surveillance |
| Cancer Pain Management | WHO ladder, opioid therapy with equianalgesic dosing, adjuvants, interventional approaches, CIPN, and palliative care |
| Guideline | Scope |
|---|---|
| Immune Checkpoint Inhibitor Adverse Events | Grade-based irAE management for all organ systems, corticosteroid protocols, immunosuppressive escalation, and rechallenge criteria |
| Oncology Survivorship Care | Surveillance by cancer type, cardio-oncology, late effects, psychosocial health, and care delivery models |
Evidence-based guideline for the safe handling, preparation, administration, and disposal of hazardous drugs in healthcare settings, including engineering controls, PPE, and exposure management.
Evidence-based guideline for prevention, assessment, and management of oral and GI mucositis in cancer patients receiving chemotherapy, radiation, and stem cell transplantation.
Evidence-based guideline for surveillance, late effects monitoring, health promotion, and comprehensive survivorship care planning for cancer survivors.
Evidence-based guideline for recognition, grading, and management of immune-related adverse events (irAEs) across all organ systems in patients receiving checkpoint inhibitor immunotherapy.
Evidence-based guideline for risk stratification, empiric therapy, prophylaxis, and management of febrile neutropenia in cancer patients.
Evidence-based guideline for emetogenic risk classification, antiemetic regimen selection, and management of chemotherapy-induced nausea and vomiting.
Evidence-based guideline for prevention, recognition, and management of chemotherapy extravasation injuries, including agent classification, antidote protocols, and follow-up care.
Evidence-based guideline for selection, insertion, maintenance, and complication management of central venous access devices in oncology patients, synthesized from multiple professional society recommendations.
Evidence-based guideline for risk assessment, prophylaxis, diagnosis, and treatment of venous thromboembolism in cancer patients, including catheter-related thrombosis.
Evidence-based guideline for assessment, pharmacological management, interventional approaches, and supportive care of cancer-related pain.